Together, the published studies do not build consensus on whether complement protein immunoreactivity is a consistent feature in MS, which areas of the CNS demonstrate immunoreactivity, or which complement proteins and pathways are involved. The gene discussed is VTN; the disease is myeloid sarcoma.